Pilot Study of (61)CuATSM-PET Imaging in Cancer Patients

Stopped early · Not applicable

Conditions studied: CNS Brain Metastases, Head and Neck Cancer, Lung Cancer, Prostate Cancer, Esophageal Cancer

In brief

Hypoxia is a key factor in malignant progression of a neoplasm. It is our aim to explore the basis for quantitative in vivo tumor imaging by Cu-61 diacetyl-bis(N4-methylthiosemicarbazone)PET imaging as a surrogate of tissue hypoxia. We hypothesize that the hypoxia levels are predictive of the tumor response to therapy. Patients will have 2 CU-ATSM PET scans done and the goal is to show spatially stable tracer distributions that correlate with tumor hypoxia. This study will serve as a pilot study for a PO1 submission

Key facts

Study ID

NCT00585117

Run by

University of Wisconsin, Madison

People needed

9

Starts

2006-12-01

Expected to finish

2012-01-01

Last updated by the study team

2019-12-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Able to tolerated a PET/CT scan
• Age 18 or older
• Patient being considered for XRT for treatment of their cancer
• Able to provide written informed consent

You may not qualify if…

• severe claustrophobia or inability to tolerate the PET scan
• pregnant or breastfeeding women
• Patients that need supplemental oxygen
• Patients enrolled in experimental treatments

Where it is running

• University of Wisconsin Hospital and Clinics — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.